FrancophonIA/ELRC3.0 huggingface dataset:
English: The risk of fracture appeared to be higher in females relative to control [11.5% vs 6.3%, Risk ratio 1.82 (95% CI 1.37 - 2.41)], than in males relative to control [5.3% vs 4.3%, Risk ratio 1.23 (95% CI 0.85 - 1.77)].
Maltese: Ir-riskju ta' ksur deher li kien ogħla fin-nisa relattiv għallkontroll [11.5% kontra 6.3%, Proporzjon ta' riskju 1.82 (95% CI 1.37 - 2.41)], milli fl-irġiel relattiv għall-kontroll [5.3% kontra 4.3%, Proporzjon ta' riskju 1.23 (95% CI 0.85 - 1.77)].
English: No clinically relevant interactions with digoxin, the CYP2C9 substrate warfarin, the CYP3A4 substrates nifedipine, ethinylestradiol or norethindrone were observed after co-administration with rosiglitazone.
Maltese: Meta rosiglitazone ingħata flimkien ma' digoxin, is-sustrat CYP2C9 warfarin, is-sustrati CYP3A4 nifedipine, ethinylestradiol jew noretindrone ma ġewx osservati l-ebda interazzjonijiet klinikament relevanti.
English: Analysis of the results for overweight patients treated with metformin after failure of diet alone showed: - a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/1,000 patient-years) versus diet alone (43.3 events/1,000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years), p=0.0034 - a significant reduction of the absolute risk of diabetes-related mortality: metformin 7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017 - a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/1,000 patient-years (p=0.021) - a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/1,000 patient-years, diet alone 18 events/1,000 patient-years (p=0.01).
Maltese: Analiżi tar-riżultati għal pazjenti b'piż eċċessiv ikkurati b'metformin wara li falliet id-dieta waħidha wrew: - tnaqqis sinifikanti fir-riskju assolut ta' kumplikazzjoni relatata mad-dijabete fil-grupp ta' metformin (29.8 każi/1,000 snin ta' kura (patient-years)) imqabbel ma' dieta waħidha (43.3 każi/1,000 snin ta' kura), p=0.0023, u mqabbel ma' gruppi ta' monoterapija kkombinata bissulphonylurea u l-insulina (40.1 każi/1,000 snin ta' kura), p=0.0034 - tnaqqis sinifikanti tar-riskju assolut ta' mwiet relatati mad-dijabete: metformin 7.5 każi/1,000 snin ta' kura, dieta waħidha 12.7 każi/1,000 snin ta' kura, p=0.017 - tnaqqis sinifikanti fir-riskju assolut ta' mwiet in generali: metformin 13.5 każi/1,000 snin ta' kura komparat ma' dieta waħidha 20.6 każi/1,000 snin ta' kura (p=0.011) u kkomparat ma' gruppi ta' monoterapija b'sulphonylurea u insulina kkombinati 18.9 każi/1,000 snin ta' kura (p=0.021) - tnaqqis sinifikanti fir-riskju assolut ta' infart mijokardjali: metformin 11-il każ/1,000 snin ta' kura, dieta waħidha 18-il każ/1,000 snin ta' kura (p=0.01).
English: PSURs
Maltese: PSUR
English: • beta-2-agonists (used to treat asthma), such as salbutamol or salmeterol
Maltese: • agonisti beta-2 (li jintużaw biex jikkuraw l-ażma), bħal salbutamol u salmeterol
English: Tel.: + 48 (0)22 576 9000
Maltese: GSK Commercial Sp. z o.o. Tel.: + 48 (0)22 576 9000
English: The clinical relevance of this decrease is unknown.
Maltese: Ir-relevanza klinika ta' dan ittnaqqis mhix magħrufa.
English: Since there is no significant in vitro inhibition of CYP1A2, 2A6, 2C19, 2D6, 2E1, 3A or 4A with rosiglitazone, there is a low probability of significant metabolism-based interactions with substances metabolised by these P450 enzymes.
Maltese: Peress li m'hemmx inibizzjoni in vitro sinifikanti ta' CYP1A2, 2A6, 2CI9, 2D6, 3A jew 4A ma' rosiglitazone, hemm probabbiltà żgħira ta' interazzjonijiet bażati fuq il-metaboliżmu ma' sustanzi metabolizzati minn dawn l-enżimi P450.
English: Stop taking Avandamet.
Maltese: Ieqaf ieħu Avandamet.
English: The red blood cells most likely represent a secondary compartment of distribution.
Maltese: Probabbilment, iċ-ċelloli ħomor tad-demm jirrappreżentaw kompartiment sekondarju ta' distribuzzjoni.
English: It cannot be excluded that other inducers (e.g. phenytoin, carbamazepine, phenobarbital, St John's wort) may also affect rosiglitazone exposure.
Maltese: Ma jistax jiġi eskluż li inducers oħra (e.ż. phenytoin, carbamazepine, phenobarbital, St John's wort) jistgħu wkoll ikollhom effett fuq lesponiment għal rosiglitazone.
English: It is assumed that the pharmacokinetics of metformin absorption is non-linear.
Maltese: Huwa presunt li lproċess farmakokinetiku ta' assorbiment ta' metformin mhux lineari.
English: This check may be repeated at intervals.
Maltese: Dan l-iċċekkjar jista' jkun ripetut f'intervalli.
English: NAME OF THE MARKETING AUTHORISATION HOLDER SmithKline Beecham Ltd
Maltese: FIS-SUQ SmithKline Beecham Ltd
English: Overall, 43%, 47% and 42% of subjects in the rosiglitazone, glibenclamide and metformin groups respectively withdrew due to reasons other than monotherapy failure.
Maltese: Meta jitqies kollox, 43%, 47% u 42% tas-suġġetti fil-grupp ta' rosiglitazone, glibenclamide u metformin rispettivament, irtiraw minħabba raġunijiet barra falliment tal-monoterapija.
English: Each tablet contains either: 1 mg rosiglitazone and 500 mg metformin; 2 mg rosiglitazone and 500 mg metformin; 2 mg rosiglitazone and 1000 mg metformin or 4 mg rosiglitazone and 1000 mg metformin.
Maltese: Kull pillola fiha jew: 1mg rosiglitazone u 500mg metformin; 2mg rosiglitazone u 500mg metformin; 2mg rosiglitazone u 1000mg metformin jew 4mg rosiglitazone u 1000mg metformin.
English: Very rare pruritis
Maltese: Rari ħafna
English: Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1000) and very rare (<1/10,000 including isolated reports).
Maltese: Il-frekwenzi huma definiti bħala: komuni ħafna (≥1/10), komuni (≥1/100 sa <1/10), mhux komuni (≥1/1,000 sa <1/100), rari (≥1/10,000, <1/1000) u rari ħafna (<1/10000 inkluż rapporti iżolati).
English: The terminal half-life for radioactivity was about 130 h indicating that elimination of metabolites is very slow.
Maltese: Il-half-life terminali għar-radjuattività kienet madwar 130 h u dan jindika li l-eliminazzjoni tal-metaboli issir bil-mod ħafna.
English: Renal function
Maltese: Renju Unit
English: cardiac ischaemia3*
Maltese: Komuni iskemja kardijaka3*
English: Nervous system disorders dizziness*
Maltese: Mard tas-sistema nervuża sturdament*
English: The incidence of heart failure on triple oral therapy was 1.4% in the main double blind study, compared to 0.4% for metformin plus sulphonylurea dual therapy.
Maltese: L-inċidenza ta' insuffiċjenza tal-qalb f'terapija orali trippla kienet ta' 1.4% fl-istudju double blind prinċipali, meta mqabbla ma' 0.4% għal terapija doppja b'metformin u sulphonylurea.
English: Glucocorticoids (given by systemic and local routes) beta-2-agonists, and diuretics have intrinsic hyperglycaemic activity.
Maltese: Glukokortikojdi (mogħtija permezz ta' rotot sistemiċi u lokali) beta-2-agonists, u djuretiċi fihom attività ipergliċemika intrinsika.
English: However, in their entirety the available data on the risk of cardiac ischaemia are inconclusive (see section 4.8).
Maltese: Madankollu, globalment id-dejta disponibbli dwar ir-riskju ta' iskemija kardijaka mhux konklussiva (ara sezzjoni 4.8).
English: The potential risk for humans is unknown.
Maltese: Ir-riskju potenzjali fuq il-bniedem mhux magħruf.
English: Don't take Avandamet.
Maltese: Tieħux Avandamet.
English: SmithKline Beecham Ltd 980 Great West Road Brentford, Middlesex TW8 9GS United Kingdom
Maltese: SmithKline Beecham Ltd 980 Great West Road Brentford, Middlesex TW8 9GS Renju Unit
English: In a prospective cardiovascular outcomes study (mean follow-up 5.5 years) the primary endpoint events of cardiovascular death or hospitalisation were similar between rosiglitazone and active comparators [HR 0.99 (95% CI 0.85 - 1.16)].
Maltese: Fi studju prospettiv dwar riżultati kardjovaskulari (medja tal-vista ta' wara 5.5 snin) l-avvenimenti tal-endpoint primarja ta' mewt kardjovaskulari jew dħul lisptar kienu simili bejn rosiglitazone u komparaturi attivi [HR 0.99 (95% CI 0.85 - 1.16)].
English: Excipients:
Maltese: Manifattur:
English: • increased weight, increased appetite
Maltese: • nervożità, palpitazzjonijiet
English: • constipation
Maltese: • kollass
English: Patients should be aware of the risk of pregnancy (see section 4.6).
Maltese: Il-pazjenti għandhom ikunu informati dwar ir-riskju ta' tqala (ara sezzjoni 4.6).
English: The major routes of metabolism are N-demethylation and hydroxylation, followed by conjugation with sulphate and glucuronic acid.
Maltese: Ir-rotot ewlenin ta' metaboliżmu huma N-demethylation u hydroxylation, segwiti permezz ta' konjugazzjoni bis-sulphate u glucuronic acid.
English: Avandamet tablets come in different strengths.
Maltese: Il-pilloli ta' Avandamet jiġu f'dożi differenti.
English: Symptoms of lactic acidosis include:
Maltese: Sintomi ta' aċidożi lattika jinkludu:
English: The following statements reflect the information available on the individual active substances (rosiglitazone and metformin).
Maltese: L-istqarrijiet segwenti jirriflettu l-informazzjoni disponibbli dwar issustanzi attivi individwali (rosiglitazone u metformin).
English: Hepatic impairment: In cirrhotic patients with moderate (Child-Pugh B) hepatic impairment, unbound Cmax and AUC were 2- and 3-fold higher than in normal subjects.
Maltese: Indeboliment tal-fwied: f'pazjenti morda b'ċirrożi b'indeboliment moderat (Child-Pugh B) tal-fwied, unbound Cmax u AUC kienu darbtejn u 3 darbiet ogħla minn f'suġġetti normali.
English: In double-blind clinical trials with rosiglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo (0.2%) and less than that of the active comparators (0.5% metformin/sulphonylureas).
Maltese: Fi provi kliniċi double blind b'rosiglitazone, l-inċidenza ta' żidiet fl-ALT aktar minn tlett darbiet ta' logħla limitu tan-normal kienet daqs tal-placebo (0.2%) u anqas minn dik tal-komparaturi attivi (0.5% meformin/sulphonylureas).
English: Cationic medicinal products that are eliminated by renal tubular secretion (e.g. cimetidine) may interact with metformin by competing for common renal tubular transport systems.
Maltese: Prodotti mediċinali katajoniċi li jiġu eliminati permezz ta'sekrezzjoni tubulari renali (e.ż. cimetidine) jistgħu ma jaqblux ma metformin billi jikkompetu għall-istess sistema ta' trasport tubulari renali.
English: 1 Hypercholesterolaemia was reported in up to 5.3% of patients treated with rosiglitazone
Maltese: 1 Iperkolesterolemija ġiet irrappurtata sa f'5.3% ta'pazjenti fuq terapija ta' rosiglitazone (monoterapija u terapija orali doppja jew trippla).
English: In the fed state, Cmax was lower (22% rosiglitazone and 15% metformin) and tmax delayed (by approximately 1.5 h rosiglitazone and 0.5 h metformin).
Maltese: Wara l-ikel, Cmax kien iktar baxx (22% rosiglitazone u 15% metformin ) u tmax ittardjat (b'madwar 1.5 h rosiglitazone u 0.5 h metformin).
English: Following administration of a dose of 850 mg, a 40% lower plasma peak concentration, a 25% decrease in AUC and a 35 min prolongation of time to peak plasma concentration was observed.
Maltese: Wara li tingħata doża ta' 850 mg, ġiet osservata konċentrazzjoni massima fil-plażma 40% iktar baxxa, tnaqqis ta' 25% f'AUC u titwil ta' 35 minuta biex il-konċentrazzjoni tal-plażma laħqet il-massimu.
English: • inflammation of the liver (hepatitis)
Maltese: • infjammazzjoni tal-fwied (epatite)
English: No difference in the number of adjudicated primary endpoint events for rosiglitazone (321/2220) versus active control (323/2227) (HR 0.99, CI 0.85-1.16) was observed, meeting the pre-defined noninferiority criterion of 1.20 (non-inferiority p = 0.02).
Maltese: Ma kienet osservata l-ebda differenza fin-numru ta' avvenimenti ta' l-endpoint primarja għal rosiglitazone (321/2220) kontra l-konroll attiv (323/2227) (HR 0.99, CI 0.85-1.16), li laħqet il-kriterju ta' nuqqas ta' inferjorità definita minn qabel ta' 1.20 (nuqqas ta' inferjorità p = 0.02).
English: GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com
Maltese: Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com
English: The maximum recommended daily dose of AVANDAMET is 8 mg rosiglitazone plus 2000 mg metformin hydrochloride.
Maltese: L-ogħla doża ta' AVANDAMET rakkomandata hija 8 mg rosiglitazone u 2000mg metformin hydrochloride.
English: An active controlled clinical trial (rosiglitazone up to 8 mg daily or metformin up to 2,000 mg daily) of 24 weeks duration was performed in 197 children (10-17 years of age) with type 2 diabetes.
Maltese: Prova klinika kkontrollata attiva (rosiglitazone sa 8mg kuljum jew metformin sa 2,000mg kuljum) li dam 24 ġimgħa sar fuq 197 tifel u tifla (eta' bejn 10 u 17-il sena) b'dijabete tat-tip 2.
English: There is limited experience with rosiglitazone in patients with elevated liver enzymes (ALT > 2.5 times the upper limit of normal).
Maltese: Teżisti esperjenza limitata ta' rosiglitazone f'pazjenti b'livell għoli ta' enzimi tal-fwied (ALT >2.5 darba l-limitu ta' fuq tan-normal).
English: This translates to a cumulative incidence of treatment failure of 10.3% for rosiglitazone, 14.8% for metformin and 23.3% for glibenclamide treated patients.
Maltese: 3% għal rosiglitazone, 14.8% għal metformin u 23.3% għal pazjenti ttrattati bi glibenclamide.
English: A study conducted in seven normal healthy volunteers showed that cimetidine, administered as 400 mg twice daily, increased metformin systemic exposure (AUC) by 50% and Cmax by 81%.
Maltese: Studju li sar f'seba' voluntiera normali u f'saħħithom wera li cimetidine amministrat f'doża ta' 400mg darbtejn kuljum, żied l-esponiment sistemiku ta' metformin (AUC) b'50% u Cmax b'81%.
English: In a monotherapy study, the incidence in females for rosiglitazone was 9.3% (2.7 patients per 100 patient years) vs 5.1% (1.5 patients per 100 patient years) for metformin or 3.5% (1.3 patients per 100 patient years) for glibenclamide.
Maltese: Fi studju b'monoterapija, l-inċidenza fin-nisa għal rosiglitazone kienet 9.3% (2.7 pazjenti kull 100 sena ta' pazjenti) vs 5.1% (1.5 pazjenti kull 100 sena ta' pazjenti) għal metformin jew 3.5% (1.3 pazjenti kull 100 sena ta' pazjenti) għal glibenclamide.
English: • gemfibrozil (used to lower cholesterol)
Maltese: • gemfibrozil (li jintuża biex ibaxxu l-kolesterol)
English: Rosiglitazone with metformin
Maltese: Rosiglitazone ma' metformin
English: Very rare hepatitis
Maltese: Rari ħafna epatite
English: AVANDAMET combines two antihyperglycaemic agents with complimentary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: rosiglitazone maleate, a member of the thiazolidinedione class and metformin hydrochloride, a member of the biguanide class.
Maltese: AVANDAMET jikkombina żewġ aġenti anti-ipergliċemiċi permezz ta' mekkaniżmu ta' azzjoni kumplimentari biex itejjeb il-kontrol tal-glukożju fid-demm f'pazjenti b'dijabete tip 2: rosiglitazone maleate, membru tal-klassi thiazolidinedione, u metformin hydrochloride, membru tal-klassi
English: The RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes) trial was a large (4,447 subjects), open-label, prospective, controlled study (mean follow-up 5.5 years) in which patients with type 2 diabetes inadequately controlled with metformin or sulphonylurea were randomised to add-on rosiglitazone or metformin or sulphonylurea.
Maltese: Il-prova RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes) kien studju kbir (4,447 individwu), open-label, prospettiv u kkontrollat (medja ta' visti ta' wara 5.5 snin) fejn pazjenti b'dijabete tat-tip 2 mhux ikkontrollata sew b'metformin jew b'sulphonylurea kienu randomised biex iżidu rosiglitazone jew metformin jew sulphonylurea.
English: OTHER
Maltese: Ir
English: • rifampicin (used to treat tuberculosis and other infections)
Maltese: • rifampicin (li jintuża jikkura t-tuberkulożi u nfezzjonijiet oħra)
English: Renal clearance of metformin is > 400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion.
Maltese: Il-clearance mill-kliewi ta' metformin hija >400 ml/min u jindika li metformin hu eliminat permezz ta' filtrazzjoni glomerulari u tisfija tubulari.
English: Randomised Treatment†
Maltese: Kura Randomised †
English: 3 In a retrospective analysis of data from 42 pooled short-term clinical studies, the overall incidence of events typically associated with cardiac ischaemia was higher for rosiglitazone containing regimens, 2.00% versus combined active and placebo comparators, 1.53% [hazard ratio (HR) 1.30 (95% confidence interval (CI) 1.004 - 1.69)].
Maltese: 3F'analiżi retrospettiva ta' tagħrif minn 42 studji kliniċi fuq tul ta' żmien qasir, miġbura flimkien, linċidenza ġenerali ta' każi assoċjati tipikament ma' iskemija kardijaka kienet ogħla fil-każ ta' terapija li jkun fiha rosiglitazone, 2.00% kontra komparaturi attivi kombinati u plaċebo, 1.53% [hazard ratio (HR) 1.30 (95% confidence interval (CI) 1.004 - 1.69)].
English: In an update to this retrospective analysis that included 10 further studies that met the criteria for inclusion, but were not available at the time of the original analysis, the overall incidence of events typically associated with cardiac ischaemia was not statistically different for rosiglitazone containing regimens, 2.21% versus combined active and placebo comparators, 2.08% [HR 1.098 (95% CI 0.809 - 1.354)].
Maltese: F'aġġornament ta' din l-analiżi retrospettiva li kienet tinkludi 10 studji oħra li laħqu l-kriterju għall-inklużjoni, iżda ma kienux disponibbli waqt l-analiżi oriġinali, l-inċidenza globali ta' avvenimenti tipikament assoċjati ma' iskemija kardijaka ma kienetx statistikament differenti għal korsijiet li fihom rosiglitazone, 2.21% kontra komparaturi attivi u plaċebo kombinati, 2.08% [HR 1.098 (95% CI 0.809 - 1.354)].
English: Data with AVANDAMET is also consistent with this combined adverse reaction profile.
Maltese: Tagħrif b'AVANDAMET huwa wkoll konsistenti ma' dan il-profil kkombinat ta' reazzjonijiet mhux mixtieqa.
English: • steroids (used to treat inflammation) such as prednisolone or dexamethasone
Maltese: • sterojdi (li jintużaw biex jikkuraw fjammazzjonijiet) bħal prednisolone jew dexamethasone
English: After an oral dose, the non-absorbed fraction recovered in faeces was 20-30%.
Maltese: Wara doża orali, il-parti mhux assorbita irkuprata mill-ippurgar kienet ta' 20-30%.
English: Musculoskeletal and connective tissue disorders bone fractures4
Maltese: Mard muskolu-skelettrali u tal-connective tissue ksur ta' l-għadam4
English: Metformin stimulates intracellular glycogen synthesis by acting on glycogen synthase.
Maltese: Metformin jistimola s-sinteżi tal-glajkoġen intraċellulari billi jaġixxi fuq glycogen synthase
English: Sodium starch glycollate Hypromellose (E464) Microcrystalline cellulose (E460)
Maltese: Sodium starch glycollate Hypromellose (E464) Microcrystalline cellulose (E460) Lactose monohydrate Povidone (E1201) Magnesium stearate.
English: • ACE inhibitors (used to treat high blood pressure), such as enalapril or captopril
Maltese: • inibituri ACE (li jintużaw biex jikkuraw pressjoni għolja), bħal enalapril u captopril
English: Nervous system disorders metallic taste
Maltese: Mard tas-sistema nervuża togħma ta' metall
English: Avandamet contains lactose
Maltese: L-inċidenza ta' aċidozi lattika
English: Frequency of adverse reaction by treatment regimen Rosiglitazone monotherapy
Maltese: Frekwenza ta' reazzjonijiet avversi skond it-terapija Monoterapija b'rosiglitazone
English: For the different dosage regimens, AVANDAMET is available in appropriate strengths.
Maltese: Għal regoli ta' trattament b'dożi differenti, AVANDAMENT jinstab f'dożi adattati.
English: The active substances are rosiglitazone and metformin.
Maltese: Is-sustanzi attivi huma rosiglitazone u metformin.
English: In controlled clinical trials, maximum metformin plasma levels (Cmax) did not exceed 4 µg/ml, even at maximum doses.
Maltese: Fi provi kliniċi kontrollati, livelli massimi fil-plażma ta' metformin (Cmax) ma qabżux l-4 μg/ml, anke b'dożi massimi.
English: There was a significant increase in heart failure (fatal and nonfatal) (HR 2.10, CI 1.35-3.27) and bone fractures (Risk Ratio 1.57, CI 1.26-1.97) in rosiglitazonecontaining treatments compared to active control (see sections 4.4 and 4.8).
Maltese: Kien hemm żjieda sinifikanti fl-insuffiċjenza tal-qalb (fatali u mhux fatali) (HR 2.10, CI 1.35-3.27) u fil-ksur fl-għadam (Proporzjon ta' Riskju 1.57, CI 1.26-1.97) fil-kura li kien fiha rosiglitazone meta mqabbel mal-kontroll attiv (ara sezzjonijiet 4.4 u 4.8).
English: ADOPT (A Diabetes Outcome Progression Trial) was a multicentre, double-blind, controlled trial with a treatment duration of 4-6 years (median duration of 4 years), in which rosiglitazone at doses of 4 to 8 mg/day was compared to metformin (500 mg to 2000 mg/day) and glibenclamide (2.5 to 15 mg/day) in 4351 drug naive subjects recently diagnosed (≤3 years) with type 2 diabetes.
Maltese: ADOPT (A Diabetes Outcome Progression Trial) kienet prova klinika kkontrollata, double-blind, f'ħafna ċentri li damet sejra għal 4-6 snin (tul ta' żmien medju ta' 4 snin), fejn rosiglitazone b'doża ta' 4 sa 8 mg kuljum tqabbel ma' metformin (500 mg sa 2000 mg kuljum) u glibenclamide (2.5 sa 15 mg kuljum) f'4351 suġġett li qatt ma ħadu din it-tip ta' mediċina u li kellhom dijanjosi reċenti (≤3 snin) ta' dijabete tat-tip 2.
English: A retrospective analysis of data from 42 pooled short-term clinical studies indicated that treatment with rosiglitazone may be associated with an increased risk of myocardial ischaemic events.
Maltese: Analiżi retrospettiva ta' dejta minn 42 studju kliniku fuq perijodu qasir miġbura f'daqqa tindika li kura b'rosiglitazone tista' tkun assoċjata ma' riskju akbar ta' avvenimenti mijokardijaċi iskemiċi.
English: • diuretics (used to get rid of water), such as furosemide or indapamide
Maltese: • dijuretiċi (li jintużaw biex ineħħu l-ilma), bħal furosemide jew indapamide
English: Tel: + 386 (0)1 280 25 00 medical.x.si@gsk.com
Maltese: GlaxoSmithKline d.o.o. Tel: + 386 (0)1 280 25 00 medical.x.si@gsk.com
English: Rosiglitazone with metformin and sulphonylurea
Maltese: Rosiglitazone ma' metformin u sulphonylurea
English: After an oral dose of metformin, tmax is reached in 2.5 h. Absolute bioavailability of a 500 mg metformin tablet is approximately 50-60% in healthy subjects.
Maltese: Biodisponibilità assoluta ta' pillola metformin tal-500 mg hi ta' madwar 50-60% f'suġġetti b'saħħithom.
English: • Avandamet is not recommended during pregnancy.
Maltese: • Treddgħax waqt li tkun qed tieħu Avandamet.
English: (You can also take this dose as two 2 mg/500 mg tablets, twice a day.)
Maltese: (Tista' wkoll tieħu din id-doża bħala żewġ 2mg/500mg, darbtejn kuljum.)
English: Metabolism and nutrition disorders lactic acidosis
Maltese: Mard marbut mal-metaboliżmu u n-nutrizzjoni aċidożi lattika
English: AVANDAMET 1 mg/500 mg film-coated tablets AVANDAMET 2 mg/500 mg film-coated tablets AVANDAMET 2 mg/1000 mg film-coated tablets AVANDAMET 4 mg/1000 mg film-coated tablets rosiglitazone/metformin HCl
Maltese: AVANDAMET, 1mg/500mg pilloli miksijin b'rita AVANDAMET, 2mg/500mg pilloli miksijin b'rita AVANDAMET, 2mg/1000mg pilloli miksijin b'rita AVANDAMET, 4mg/1000mg pilloli miksijin b'rita rosiglitazone/metformin HCl
English: Children and adolescents: Population pharmacokinetic analysis including 96 paediatric patients aged 10 to 18 years and weighing 35 to 178 kg suggested similar mean CL/F in children and adults.
Maltese: Analiżi farmakokinetika ta'popolazzjoni li kienet tinkludi 96 pazjent pedjatriku li l-eta' tagħhom kienet bejn l-10 u t-18-il sena u li kienu jiżnu bejn il-35 u l-178 kg implikat medja tixtiebaħ ta' CL/F bejn it-tfal u l-adulti.
English: Gastrointestinal disorders Constipation
Maltese: Mard gastro-intestinali stitikezza